Characterization of PTZ-Induced Seizure Susceptibility in a Down Syndrome Mouse Model That Overexpresses CSTB
Open Access
- 30 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27845
Abstract
Down syndrome (DS) is a complex genetic syndrome characterized by intellectual disability, dysmorphism and variable additional physiological traits. Current research progress has begun to decipher the neural mechanisms underlying cognitive impairment, leading to new therapeutic perspectives. Pentylenetetrazol (PTZ) has recently been found to have positive effects on learning and memory capacities of a DS mouse model and is foreseen to treat DS patients. But PTZ is also known to be a convulsant drug at higher dose and DS persons are more prone to epileptic seizures than the general population. This raises concerns over what long-term effects of treatment might be in the DS population. The cause of increased propensity for epilepsy in the DS population and which Hsa21 gene(s) are implicated remain unknown. Among Hsa21 candidate genes in epilepsy, CSTB, coding for the cystein protease inhibitor cystatin B, is involved in progressive myoclonus epilepsy and ataxia in both mice and human. Thus we aim to evaluate the effect of an increase in Cstb gene dosage on spontaneous epileptic activity and susceptibility to PTZ-induced seizure. To this end we generated a new mouse model trisomic for Cstb by homologous recombination. We verified that increasing copy number of Cstb from Trisomy (Ts) to Tetrasomy (Tt) was driving overexpression of the gene in the brain, we checked transgenic animals for presence of locomotor activity and electroencephalogram (EEG) abnormalities characteristic of myoclonic epilepsy and we tested if those animals were prone to PTZ-induced seizure. Overall, the results of the analysis shows that an increase in Cstb does not induce any spontaneous epileptic activity and neither increase or decrease the propensity of Ts and Tt mice to myoclonic seizures suggesting that Ctsb dosage should not interfere with PTZ-treatment.Keywords
This publication has 93 references indexed in Scilit:
- Intracellular aggregation of human stefin B: confocal and electron microscopy studyBiology of the Cell, 2010
- Molecular basis of pharmacotherapies for cognition in Down syndromeTrends in Pharmacological Sciences, 2010
- Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndromeProceedings of the National Academy of Sciences, 2008
- Dscam diversity is essential for neuronal wiring and self-recognitionNature, 2007
- Classification of Human Chromosome 21 Gene-Expression Variations in Down Syndrome: Impact on Disease PhenotypesThe American Journal of Human Genetics, 2007
- Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomyBMC Genomics, 2007
- Gene expression variation in Down's syndrome mice allows prioritization of candidate genesGenome Biology, 2007
- Modeling Chromosomes in Mouse to Explore the Function of Genes, Genomic Disorders, and Chromosomal OrganizationPLOS Genetics, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Amino acid sequence of the intracellular cysteine proteinase inhibitor cystatin B from human liverBiochemical and Biophysical Research Communications, 1985